CLINICAL_TRIALS
trial_result
· 2024-01-18
Clinical Trial Update: A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors [Phase 1, Phase 2]
Summary
A phase 1/2 trial evaluating BLZ945 alone or with PDR001 in advanced solid tumors was terminated; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-18